Log in to search using one of your social media accounts:


Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?

A growing body of evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be a powerful option to improve the cardiovascular (CV) prognosis in high CV-risk patients with type 2 diabe...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Commentary Source Type: research

Related Links:

More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes Type 2 | Endocrinology | Heart | Invokana | SGLT2 Inhibitors | Sodium